Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility Study

Cancer, Breast Clinical Trial

— VAPOR-C  

Official title:

Volatile Anaesthesia and Perioperative Outcomes Related to Cancer (VAPOR-C): A Feasibility Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04074460
• Other study ID #: 16/144
• Status: Completed
• Phase: Phase 4
• Start date: August 27, 2017
• Est. completion date: June 30, 2020

Study information

• Verified date: June 2022
• Source: Peter MacCallum Cancer Centre, Australia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A multicentre, prospective randomized, active-controlled feasibility trial of volatile-based anaesthesia vs. propofol-based total intravenous anaesthesia to investigate the impact of anaesthesia on long-term (i.e. 5-years) patient cancer outcomes in patients undergoing elective major cancer surgery.

Description:

This study aims to assess the feasibility of conducting a phase IV, multi-centre, single-blinded, randomized control trial (VAPOR-C (Main)).

Primary aims To measure the ability to recruit eligible patients into the study.

To measure the ability to successfully deliver each of the two anaesthetic techniques (volatile-based general anaesthesia and propofol-based anaesthesia) according to the research protocol.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 169
• Est. completion date: June 30, 2020
• Est. primary completion date: October 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Male or female

• Age 18-80 years

• Elective surgery

• Major cancer surgery expecting to last two or more hours, for:

• Breast (mastectomy or segmentectomy plus sentinel node dissection)

• Colorectal

• Lung

• Prostate

• Melanoma (excision of melanoma plus lymph node dissection AND/OR skin flap construction

• Other major cancer surgeries (e.g. oesophagectomy, head and neck cancer, etc.)

Exclusion Criteria

• Palliative surgery for end-stage disease with no curative intent

• Emergency surgery

• Extensive comorbid disease, i.e. American Society of Anesthesiologists (ASA) Score > 4

• Age <18 or >80 years old

• Refusal or inability to provide valid informed consent

• Risk of severe postoperative nausea and vomiting (PONV risk score >3)

• Previous allergy or contraindication to either anaesthetic medication

• Indication for gas induction of anaesthesia

• Currently enrolled in another clinical trial unless agreed by the coordinating principal investigator and site principal investigator that co-enrolment can occur.

Related Conditions & MeSH terms

• Breast Neoplasms
• Cancer Colorectal
• Cancer Melanoma Skin
• Cancer Prostate
• Cancer, Breast
• Cancer, Lung
• Cancer, Other
• Lung Neoplasms

Intervention

Drug:
• Propofol
General Anaesthesia
• isoflurane, sevoflurane or desflurane
General Anaesthesia

Locations

Country	Name	City	State
Australia	Peter MacCallum Cancer Centre	Melbourne

Sponsors (4)

Lead Sponsor	Collaborator
Peter MacCallum Cancer Centre, Australia	M.D. Anderson Cancer Center, Melbourne Health, The Alfred

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To measure the ability to recruit eligible patients into the study.	The study protocol will be assessed as feasible if a recruitment rate of at least 75% is achieved.	18 months
Primary	To measure the ability to successfully deliver each of the two anaesthetic techniques (volatile-based general anaesthesia and propofol-based anaesthesia) according to the research protocol.	The study protocol will be assessed as feasible if a successful delivery rate of at least 90% is achieved.	18 months
Secondary	To identify that all sites can capture data within the electronic case report form (eCRF) and utilize the electronic data capturing system (REDCap).	All missing data to be recorded including reason for missing data, where available. Quantitative and qualitative analysis of reasons for missing data will be analysed by : Number of fields with missing data (percentage) and reason for missing data ( qualitative descriptor). Fields with >1 missing data point will be analysed for reasons for failure.	18 months
Secondary	To test the efficiency of the centralized patient enrolment and computer randomization system.	Number of events of failed randomisation will be recorded on eCRF (under 'treatment of subjects"). Quantitative analysis of failed randomisation (reported as %) as well as descriptive reason for failure will be recorded and analysed. This will allow shortcomings in the use of the computer-generated centralised randomisation program to be identified and ratified.	18 months